Time to progression of the tumour · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus oxaliplatin changes all‐cause mortality at 1 year compared with 5‐fluorouracil plus cisplatin plus radiotherapy (very low certainty).
1 finding from 1 review
Serious adverse events · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus oxaliplatin changes serious adverse events compared with 5‐fluorouracil plus cisplatin plus radiotherapy (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to progression of the tumour · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus mitomycin C changes all‐cause mortality at 1 year compared with capecitabine plus mitomycin C (very low certainty).
1 finding from 1 review
Serious adverse events · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus mitomycin C changes overall response rate compared with capecitabine plus mitomycin C (very low certainty).
1 finding from 1 review
Time to progression of the tumour · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grade 1 ‐ 4 thrombocytopenia · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus mitomycin C changes grade 1 ‐ 4 thrombocytopenia compared with capecitabine plus mitomycin C (very low certainty).
1 finding from 1 review
Overall survival ‐ Fixed dose rate gemcitabine · advanced pancreatic cancer
Various types of chemotherapy leads to lower overall survival ‐ Fixed dose rate gemcitabine compared with gemcitabine (high certainty).
1 finding from 1 review
Gemcitabine · healthcare staff who handle infusional hazardous drugs
It is very uncertain whether closed‐system transfer device plus safe handling changes gemcitabine compared with safe handling alone (very low certainty).
1 finding from 1 review
RR 0.96 [0.6, 1.54]
Studies not reported
Very low
5‐fluorouracil, cytarabine, gemcitabine, irinotecan, docetaxel, paclitaxel, vinorelbine, multiple drugsϯ · healthcare staff who handle infusional hazardous drugs
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Cytarabine, gemcitabine, and irinotecan · healthcare staff who handle infusional hazardous drugs
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
5‐fluorouracil, cytarabine, gemcitabine, and irinotecan · healthcare staff who handle infusional hazardous drugs
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Cyclophosphamide, ifosfamide, or gemcitabine · healthcare staff who handle infusional hazardous drugs
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
All‐cause mortality: 1‐year overall survival · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant S‐1 changes all‐cause mortality: 1‐year overall survival compared with gemcitabine (very low certainty).
1 finding from 1 review
All‐cause mortality: 2‐year overall survival · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant S‐1 changes all‐cause mortality: 2‐year overall survival compared with gemcitabine (very low certainty).
1 finding from 1 review